MitraTest A Novel Non-invasive Dna Methylation Test for Melanoma
- Coordinator
- Mitra Bio Limited, United Kingdom
- Runs
- 1 November 2025 to 31 October 2027
- Status
- Running
- EU funding
- €2.5m
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 101247537
What the project is doing
In the project's own words, from its summary on CORDIS.
Early cancer detection is a key to improve survival rates. For melanoma the survival falls from >98% at Stage 1 to 22% at Stage 4.Currently, skin biopsy is the only method of melanoma detection. It is an expensive and invasive procedure. Our patented technology, is a combination of a unique non-invasive tape strip skin sample collection technique and proprietary DNA methylation panel specific for melanoma. This will allow quick and inexpensive testing for melanoma at GP level and as an at-home test kit.
Our proof of concept study with Guy’s Hospital (UK) showed over 95% specificity and 85% sensitivity in detecting melanoma compared to standard biopsy procedures. Mitra Bio is a female-led team of 6 scientists and business developers with experience in building diagnostics platforms. We aim to improve melanoma detection and reduce melanoma health and economic burden, which currently results in 15K deaths/year in the EU.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Mitra Bio Limited | London | United Kingdom | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI